|
1. |
DNA topoisomerase targeting drugs: mechanisms of action and perspectives |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 811-822
Hugues Malonne,
Ghanem Atassi,
Preview
|
PDF (926KB)
|
|
摘要:
The nuclear enzymes DNA topoisomerases I and II appeared as cellular targets for several antitumor drugs: campthotecin derivatives interacting with topoisomerase I, and actinomycin D, anthracycline derivatives, elliptinium acetate, mitoxantrone, epipodophyllotoxine derivatives, amsacrine and a new olivacine derivative, NSC-6596871 (S 16020-2), which interact with topoisomerase II. The functions of these enzymes are numerous and important since they are critical for DNA functions and cell survival. Despite the fact that they share the same target, topoisomerase II inhibitors have different mechanisms of action. Two principle types of induced alterations are involved in cellular resistance to topoisomerase II drugs: qualitative or quantitative alteration of the enzyme and/or increased drug efflux due to overexpression of P-glycoprotein. S 16020-2, a new olivacine derivative with a high antitumor activity against solid tumors, shows a potent cytotoxic effect against tumor cells expressing P-glycoprotein. This observation suggests that the comprehension of the respective effects of topoisomerase inhibitors and the precise knowledge of their mechanisms of resistance would improve the use of this therapeutic class in the clinic within rational chemotherapeutic combinations.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
2. |
A phase I study of ambulatory continuous infusion paclitaxel |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 823-828
Keith Skubitz,
Preview
|
PDF (520KB)
|
|
摘要:
Chemotherapy given by continuous infusion may have different toxicity profiles and efficacy than when given by bolus administration. Thirty-one patients with refractory tumors entered a phase I trial in which paclitaxel was administered for 7 days by continuous infusion every 28 days. Only one patient required hospitalization for treatment, because of an initial poor performance status, and most carried out normal activities on an ambulatory basis. After the first three patients, patients were entered in cohorts of five with the starting dose of 120 mg/m2. Each subsequent cohort was begun at a dose 10% higher than the previous cohort. Later courses within each cohort were increased 10% in an individual patient, if toxicity allowed. Nausea was rare. Of 15 patients with a soft tissue sarcoma refractory to doxorubicin, dacarbazine, ifosfamide, and etoposide, there were: one partial response (PR), five stable diseases and eight progressive; one patient was not evaluable for response. The PR occurred in a patient with a very aggressive sarcoma and very bulky disease, and was maintained for more than 1 year. We conclude that paclitaxel given by ambulatory continuous i.v. infusion is well tolerated with a maximally tolerated starting dose of 160 mg/m2
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
3. |
Phase I study of VRCTC-310, a purified phospholipase A2purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 829-834
Luis Costa,
Horacio Miles,
Roberto Diez,
Carlos Araujo,
Carlos Molina,
Juan Cervellino,
Preview
|
PDF (493KB)
|
|
摘要:
A phase I study was performed to evaluate the maximum tolerated dose (MTD), safety profile and pharmacokinetic data with VRCTC-310, a natural product derived from purified snake venom fractions, with phospholipase A2activity and inhibitory effects against human and murine tumor cell lines. Fifteen patients with refractory malignancies were entered after providing written informed consent. VRCTC-310 was administered as an intramuscular injection daily for 30 consecutive days. Doses were escalated from 0.0025 to 0.023 mg/kg. Toxicities included local pain at the injection site, eosinophilia, reversible diplopia and palpebral ptosis. Dose escalation was stopped at 0.023 mg/kg, when two patients had developed anaphylactoid reactions. Both cases had high VRCTC-310-specific IgG by EIA. MTD was 0.017 mg/ kg and the recommended dose for phase II studies is 0.017 mg/kg. Stabilization was found in six patients.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
4. |
Pharmacokinetics of methotrexate–albumin conjugates in tumor-bearing rats |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 835-844
Gerd Stehle,
Andreas Wunder,
Hannsjorg Sinn,
Hans Schrenk,
Sandra Schiitt,
Eva Frei,
Gernot Hartung,
Wolfgang Maier-Borst,
Dieter Heene,
Preview
|
PDF (892KB)
|
|
摘要:
Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate (MTX) as antineoplastic drug. The conjugation procedure yielded conjugates with an approximate 1:1 molar loading rate (MTX(1)-RSA). In the first part of the study a residualizing [111ln]DTPA protein label was used for mapping in vivo the catabolic sites of the native carrier protein and of the MTX(1)-RSA drug conjugate in Walker 256 carcinosarcoma bearing rats. The tumor accumulation was about 14% of the injected dose for the RSA and MTX(1)-RSA tracers after 24 h. Tracer entrapment by organs with an active mononuclear phagocyte system was low (liver below 7% and spleen below 1.5% of the injected dose after 24 h). The 1:1 conjugation of MTX to RSA did not decisively alter the pharmacokinetic properties nor the tumor or tissue distribution of the native carrier protein RSA. In the second part of the study the different properties of the MTX(1)-RSA conjugate were compared with MTX in vivo. About 2 mg MTX/ kg body weight either of the drug conjugate or of the original drug were injected after being additionally spiked with radiolabeled tracers. Plasma concentrations were simultaneously determined by immunological and radioactive means. After 24 h about 12% MTX(1)-RSA was found in circulation compared to 0.03% MTX. Favorable tumor accumulation rates of about 14% were achieved for MTX(1)-RSA versus 0.04% for MTX. About 45-fold more of the injected dose of [3H]MTX accumulated in the liver as compared to the tumor (1.5 versus 0.03%) after 24 h. Conjugation of MTX to RSA reversed this ratio in favor of the tumor to 1:1.4 (13.6 versus 9.6%). In conclusion, the potential therapeutic benefit of the MTX(1)-RSA conjugate lies in its very long tumor exposure time and its improved tumor accumulation rate compared to conventional MTX. In addition the conjugation to albumin might enhance the therapeutic effects over those achieved by long-term continuous infusion of MTX, as MTX(1)-RSA enters the cells by a different uptake mechanism. This might also help to circumvent MTX resistance mechanisms, such as a reduction in folate receptor numbers or impaired MTX polyglutamylation.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
5. |
Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 845-852
Mario Bigioni,
Carmela Salvatore,
Carla Palma,
Stefano Manzini,
Fabio Animati,
Paolo Lornbardi,
Graziella Pratesi,
Rosanna Supino,
Franco Zunino,
Preview
|
PDF (635KB)
|
|
摘要:
MEN 10710 is a new synthetic distamycin derivative possessing four pyrrole rings and a bis-(2-chloroethyl)-aminophenyl moiety linked to the oligopyrrole backbone by a flexible butanamido chain. Its biological properties have been investigated in comparison with the structurally related compound, tallimustine (FCE24517), and the classical alkylating agent, melphalan (L-PAM). Cytotoxic potency of MEN 10710 was increased from 10- to 100-fold, as compared to tallimustine or L-PAM in murine L1210, human LoVo and MCF7 tumor cell lines. MEN 10710 was still active against L1210/L-PAM leukemic cells, while a partial cross-resistance was observed in LoVo/DX and in MCF7/DX cells selected for resistance to doxorubicin and expressing a MDR phenotype. Treatment with verapamil (VRP) reduced the resistance to tallimustine, but not to MEN 10710, in MCF7/DX cells. The cytotoxic effects reflect in vivo antitumor potency and toxicity in the treatment of human tumor xenografts. MEN 10710 was more effective in A2780/DDP, an ovarian carcinoma selected for resistance to cisplatin. On the other hand, the IC30for inhibiting murine granulocyte/macrophage colony formation was 50 times higher for MEN 10710 than for tallimustine, suggesting a lower myelotoxic potential. In conclusion, the particular biological profile of MEN 10710 characterized by a marked cytotoxic potency, an interesting antitumor efficacy and a reduced in vitro myelosuppressive action may represent a further improvement in the rational design of a novel distamycin-related alkylating compound.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
6. |
Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 853-858
Ying Wang,
Surinder Aggarwal,
Preview
|
PDF (555KB)
|
|
摘要:
Cisplatin (9 mg/kg) or taxol (20 mg/kg) treatment of Wistar rats produced a sharp decrease in inducible nitric oxide synthase (iNOS) and gastrin in the pyloric region of the stomach, and an increase in iNOS and somatostatin in the pancreatic islets. Nitric oxide (NO) functions as a relaxation factor in the smooth muscle of the muscularis mucosa while gastrin plays an important role in the gastroprotection of the mucosa through NO. It is proposed that a decline of the iNOS and gastrin after cisplatin or taxol treatments is related to distention of the stomach, and possibly nausea and vomiting. Hyperglycemia and glucose intolerance after cisplatin treatment may be caused by increases of somatostatin and iNOS in the pancreatic islets. Combination therapy with cisplatin and taxol seems to ameliorate various toxicities due to these two individual drugs.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
7. |
In vitro toxicity studies with mitomycins and bleomycin on endothelial cells |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 859-868
Luc Dirix,
Martha Libura,
Jolantha Libura,
Peter Vermeulen,
Ernst De Bruijn,
Allan Van Oosterom,
Preview
|
PDF (909KB)
|
|
摘要:
Pulmonary side effects are increasingly observed as doselimiting toxicity (DLT) of cancer treatment. The available preclinical models have a limited predictive value for lung toxicity in humans. We have attempted to elucidate potential mechanisms involved in these reactions, by studying the effects on cells, possibly involved in these reactions after in vitro exposure to drugs with known lung toxic effects. We have investigated the effects of bleomycin (BLM), mitomycin C (MMC), KW-2149 and its two known metabolites, M16 and M18, on oxygen radical production by granulocytes, on cytokine production: interleukin (IL)-6, transforming growth factor (TGF)-β tumor necrosis factor (TNF)-α by a human macrophage cell line (THP-1), by human endothelial cells (HVEC and HMEC) and a human colorectal cancer cell line (DLD-1), and on the cytotoxicity on endothelial cells in both confluent and non-confluent culture. The generation of oxygen radicals by normal and pre-stimulated granulocytes was not increased after preincubation with any of the drugs, at the concentrations tested. None of the cytokines (IL-6, TNF-α or TGF-β ) was found significantly increased in culture medium after exposure to any of the mitomycins. This was in contrast with the effect of BLM incubation, causing a rise in TGF-β concentration. Both types of endothelial cells showed a dose-dependent, exposure duration-dependent, proliferation inhibition for all agents tested. This inhibitory effect was clearly proliferation dependent as shown by the increased inhibition in semi-confluent as opposed to confluent endothelial cell cultures. Both mitomycins tested were more cytotoxic than BLM to both confluent and proliferating endothelial cells.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
8. |
Comparative effect of verapamil, cyclosporin A and SDZ PSC 833 on rhodamine 123 transport and cell cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotein |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 869-875
Jordi Petriz,
Joaqufn Sanchez,
Joan Bertran,
Joan Garcfa-Lopez,
Preview
|
PDF (567KB)
|
|
摘要:
The product of the mdr1 gene, P-glycoprotein (P-gp), represents a common mechanism of cellular resistance to a wide variety of structurally and functionally unrelated drugs. A range of structurally different P-gp inhibitors, such as verapamil, cyclosporin A and SDZ PSC 833, have been shown to modify multidrug resistance (MDR). We used flow cytometry to investigate in vitro modulation of P-gp-dependent efflux of rhodamine 123 (Rh123). The capacity to modulate the MDR phenotype of vinblastine-resistant Chinese hamster ovary (CHO) cells was assessed by analyzing the concentration of modulator needed to decrease the Rh123 mean fluorescence intensity by 50%. We found that the cyclosporin derivative SDZ PSC 833 was significantly more effective than cyclosporin A and verapamil, either in the presence or absence of fetal calf serum-supplemented media. This study indicates that analysis of Rh123 efflux modulation can be used to determine the optimal doses of MDR inhibitors in vitro and suggests that more than one modulator is needed to measure P-gp function, since verapamil had no effect on Rh123 modulation when MDR cells were used.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
9. |
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 876-885
E Raymond,
C Buquet-Fagot,
S Djelloul,
J Mester,
E Cvitkovic,
P Allain,
C Louvet,
C Gespach,
Preview
|
PDF (769KB)
|
|
摘要:
Oxaliplatin, classical [5-fluorouracil (5-FU)] and non-classical (AG337) thymidylate synthase inhibitors have shown promising activity in the treatment of cancer. This study investigates the cytotoxic effects of oxaliplatin in combination with 5-FU and AG337 in cultured human colon (HT29, CaCo2), breast (MCF-7, MDA-MB-231) and ovarian (2008) cancer cell lines, and their derived counterparts selected for their resistance to 5-FU (HT29-5-FU), doxorubicin (MCF-7mdr) or cisplatin (2008C13). Therapeutic experiments were conducted in mice bearing colon-HT29 xenografts and in the GR hormone-independent mammary carcinoma model. In vitro, oxaliplatin shows potent cytotoxic activity in colon (IC50 from 2.1 +1.1 to 5.9 ± 1.7 µM), ovarian (IC50=10 ± 1.6 µM) and breast cancer cells (IC50from 7.4+2.7 to 17.9 +7.1µM). Oxaliplatin was a potent inhibitor of DNA synthesis and bound to cellular DNA. Surprisingly, the overall amount of oxaliplatin DNA binding was significantly inferior to that induced by isocytotoxic concentrations of cisplatin in HT29 (p=0.026). In vitro, synergistic antiproliferative effects were observed when oxaliplatin was added to 5-FU and AG337. Those synergistic effects of combinations were maintained in colon HT29-5-FU cancer cells. In vivo, 5-FU increased significantly the antitumor activity of oxaliplatin in HT29 xenografts (p=0.0036), and similarly 5-FU and AG337 increased the activity of oxaliplatin in the GR tumor model (p=0.0012). These data may encourage further clinical investigation of oxaliplatin in combination with classical and non-classical thymidylate synthase inhibitors in the treatment of human cancers.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
10. |
The mechanism of locally enhanced production of tumor necrosis factor- α in tumor tissues by the administration of a new synthetic lipid A analog, ONO-4007, in hepatoma-bearing rats |
|
Anti-Cancer Drugs,
Volume 8,
Issue 9,
1997,
Page 886-893
Yasuhiro Kuramitsu,
Youichi Ohiro,
Kazuhiro Matsushita,
Manabu Obara,
Masanobu Kobayashi,
Masuo Hosokawa,
Preview
|
PDF (586KB)
|
|
摘要:
ONO-4007 is a new synthetic lipid A analog with low endotoxic activities. We previously found that ONO-4007 induced the production of tumor necrosis factor (TNF)-a in rat hepatoma KDH-8 tumor tissues and brought about the regression of transplanted KDH-8 cells. By contrast, ONO- 4007 did not induce TNF-α production in spleens and sera 90 min after treatment. In the present study we attempted to elucidate how ONO-4007 induces TNF-α production in tumor tissues locally. We found that extracellular matrix including gelatin, fibronectin and Matrigel® did not induce TNF-α production in splenocytes treated with ONO-4007 in vitro. However, splenocytes co-cultured with cKDH-8/11 tumor cells in the presence of ONO-4007 produced more TNF-a than splenocytes cultured by themselves in the presence of ONO-4007. The stimulation of cKDH-8/11 cells in the presence of ONO-4007 for splenocytes to produce TNF-a depended on the type of contact between the cells. The cKDH-8/11 cells fixed in formalin were not able to induce TNF-α production of splenocytes even in the presence of ONO-4007. However, syngeneic fibrosarcoma cell line KMT- 17/A3, allogeneic hepatocellular carcinoma cell line LDH and rat lung endotherial cell line RLE induced TNF-α production in splenocytes, but their stimulation was weaker than that of cKDH-8/11. The soluble form of the cKDH-8/11 cell membrane did not stimulate splenocytes to produce TNF-α in the presence of ONO-4007. cKDH-8/11 cells did not stimulate the splenocytes devoid of macrophages to produce TNF-α in the presence of ONO-4007.
ISSN:0959-4973
出版商:OVID
年代:1997
数据来源: OVID
|
|